View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 6, 2020updated 12 Jul 2022 11:48am

Relief Therapeutics studies Aviptadil for Covid-19-related ARDS

Relief Therapeutics is conducting a US Food and Drug Administration (FDA)-approved Phase II clinical trial at New York University Langone (NYU Langone Health) to assess Aviptadil for Covid-19-related acute respiratory distress syndrome (ARDS).

Relief Therapeutics is conducting a US Food and Drug Administration (FDA)-approved Phase II clinical trial at New York University Langone (NYU Langone Health) to assess Aviptadil for Covid-19-related acute respiratory distress syndrome (ARDS).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The multi-centre study will involve patients on mechanical ventilation. It will investigate the drug’s ability to reduce mortality and improve the condition of the patient’s lungs to transfer oxygen to the body.

Led by the company’s US partner, NeuroRx, the trial is part of the FDA’s Coronavirus Treatment Acceleration Program (CTAP).

NeuroRx CEO Jonathan Javitt said: “In a previous trial of VIP for ARDS in patients with sepsis, seven of eight patients on mechanical ventilation showed substantial improvement and six ultimately left the hospital alive.

“Patients on ventilators for Covid-19 have less than a 50% chance of survival. If the early results can be replicated in ARDS caused by Covid-19, this treatment could have a major impact both on Covid-19 survival and on the availability of ventilators for those in desperate need.”

Aviptadil (RLF-100) is a Vasoactive Intestinal Polypeptide (VIP) formulation that is available in Europe to treat erectile dysfunction. Relief Therapeutics noted that VIP is highly concentrated in the lung and blocks various inflammatory cytokines.

The drug received orphan drug designation in the US and EU to treat ARDS. Relief Therapeutics also has FDA and EU orphan drug designations for the use of VIP in pulmonary hypertension and sarcoidosis indications.

Death among Covid-19 patients is known to be partly caused by a ‘cytokine storm’ in the lungs, where the virus induces inflammatory molecules called ‘cytokines’.

Cytokines cause the air sacs of the lungs to fill with water, making the sacs impermeable to oxygen, even with mechanical ventilation.

In animal models of respiratory distress, acute lung injury and inflammation, VIP demonstrated a potent anti-cytokine activity.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena